Chennai, July 1 -- Highlights:
* India has joined the global NeoSep1 trial to identify safer antibiotic combinations for drug-resistant newborn sepsis
* Around 3,000 newborns across Asia and Africa will //be enrolled by 2028 to improve sepsis treatment
* The findings could help update WHO treatment guidelines and reduce newborn deaths linked to antimicrobial resistance
India has joined the global NeoSep1 clinical trial, led by the Global Antibiotic Research and Development Partnership (GARDP) , to identify safer and more effective antibiotic combinations for newborns with drug-resistant sepsis ( ref1 ).
The study will enroll around 3,000 newborns across Asia and Africa by 2028 and could help update international treatment guidelines for one of the world's deadliest newborn infections.
According to the Indian Journal of Microbiology Research review , India accounts for nearly one-fifth of global neonatal deaths attributed to sepsis , highlighting the country's disproportionately high burden ( ref2 ).
The review also reports that around 14-15% of hospitalized newborns develop clinical sepsis, while 6-7% have culture-confirmed infections , emphasizing the urgent need for better diagnosis and effective antibiotic treatment.
According to the Global Antibiotic Research and Development Partnership (GARDP) , the trial aims to provide doctors with stronger scientific evidence to choose the most effective antibiotic combinations while reducing deaths caused by antimicrobial resistance (AMR).
Can the Trial Change Newborn Sepsis Treatment?
NeoSep1 is the world's first large international clinical trial specifically designed to evaluate multiple antibiotic combinations for newborns with sepsis caused by drug-resistant bacteria.
Unlike traditional studies that compare only one treatment against another, NeoSep1 uses an innovative Personalized Randomized Controlled Trial (PRACTical) design. This allows doctors to compare several antibiotic regimens at the same time while considering local antibiotic resistance patterns, medicine availability, and hospital treatment practices.
The study plans to recruit around 3,000 newborns across Asia and Africa by the end of 2028 . According to GARDP, babies have already been enrolled in South Africa, Kenya, Ghana, and India , while hospitals in Vietnam, Pakistan, Bangladesh, Malaysia, Uganda, and several other countries are joining the programme.
Researchers believe the results could provide the strongest evidence yet for updating national and international neonatal sepsis treatment guidelines.
What Did the First Phase of the NeoSep1 Trial Discover?
The NeoSep1 programme has already completed its first phase in South Africa and Kenya.
According to GARDP and Nature Africa , researchers successfully established the safest and most appropriate doses for two older antibiotics- fosfomycin and flomoxef -when used in combination with other antibiotics in newborns.
This was an important milestone because newborns process medicines very differently from adults. Determining the correct dose helps maximize treatment effectiveness while reducing the risk of toxicity.
The current second phase is building on those findings by comparing several antibiotic combinations across multiple countries.
Unlike conventional trials, researchers are not simply asking whether one antibiotic works better than another. Instead, they are identifying which combinations perform best under different local resistance patterns and healthcare settings.
According to GARDP, this evidence is expected to guide future WHO recommendations and national treatment guidelines while helping hospitals choose antibiotic regimens that remain effective against resistant bacteria.
Why Is Drug-Resistant Newborn Sepsis Becoming a Global Emergency?
According to Nature Africa, neonatal sepsis remains one of the most neglected causes of newborn deaths despite major improvements in child survival over the past two decades ( ref3 ).
Every year, nearly three million newborns develop neonatal sepsis worldwide . More than 90% of deaths occur in low- and middle-income countries , where access to rapid diagnosis and effective antibiotics is often limited.
Nature Africa reports that while vaccines have significantly reduced infections caused by organisms such as Streptococcus pneumoniae, hospitals are now seeing more infections caused by highly drug-resistant bacteria that do not respond to standard antibiotics.
Many newborns become critically ill within hours because their immune systems are still immature. Without prompt treatment, infection can rapidly progress to organ failure, septic shock, and death.
Why Are Current Antibiotics No Longer Enough?
According to GARDP , doctors have relied on the same first-line antibiotics for newborn sepsis for several decades . However, these medicines are increasingly failing because bacteria have become resistant.
According to the recent review, resistance has become a major challenge across Indian neonatal intensive care units (NICUs) ( ref4 ).
The review also highlights several challenges contributing to poor outcomes in India:
* Delayed diagnosis because blood cultures often miss infections.
* Limited access to advanced molecular diagnostic tests.
* Frequent use of broad-spectrum antibiotics before laboratory confirmation.
* Rising multidrug-resistant (MDR) bacteria inside neonatal intensive care units.
* Differences in resistance patterns between hospitals, making one standard treatment less effective across the country.
According to Nature Africa, very few antibiotics developed over the past two decades have been specifically tested or approved for newborns . As a result, doctors often have to estimate doses using data from adults or older children, increasing uncertainty during treatment.
How Will NeoSep1 Improve Treatment for Newborn Sepsis?
According to GARDP, NeoSep1 is not testing a single new antibiotic . Instead, it is comparing multiple combinations of existing antibiotics to identify which treatment works best against drug-resistant infections in different hospitals.
According to Nature Africa, this allows doctors to choose from several scientifically selected treatment options based on local antibiotic resistance patterns, medicine availability and prescribing practices.
Researchers can therefore compare several antibiotic regimens simultaneously instead of testing only one drug against another.
This flexible approach reflects real-world hospital settings, where the bacteria causing infections and their resistance patterns often vary from one region to another.
The trial is also expected to generate evidence that can support future updates to WHO and national neonatal sepsis treatment guidelines.
Current Treatment vs NeoSep1 Approach td{ padding:10px; } th{ background: #187681; color:white; } Current Standard Care NeoSep1 Trial Approach Relies mainly on standard first-line antibiotics such as ampicillin and gentamicin. Evaluates several antibiotic combinations against the current standard treatment. Same treatment may be used despite different antibiotic resistance patterns. Treatment options can be adapted to local resistance patterns using the PRACTical trial design. Limited evidence is available specifically for newborn antibiotic dosing. Builds on Phase 1 data that established safe dosing for fosfomycin and flomoxef in newborns. Few clinical trials focus exclusively on newborn sepsis. One of the largest international clinical trials dedicated to neonatal sepsis. Existing guidelines are based on limited evidence from many regions. Findings are expected to help update national and international treatment guidelines.
Why Does Antimicrobial Resistance Make Sepsis More Dangerous?
According to GARDP , antimicrobial resistance (AMR) has become one of the biggest threats to newborn survival.
The organization estimates that around three million newborns develop sepsis every year , with the highest burden seen in Asia and sub-Saharan Africa.
The Global Research on Antimicrobial Resistance (GRAM) study, cited by GARDP, estimated that in 2019 , approximately 238,500 newborn deaths across South Asia, Southeast Asia and Oceania were associated with antimicrobial resistance , including 63,200 deaths directly caused by infections that no longer responded to standard antibiotics.
Vaccine-preventable infections have declined over recent years, but drug-resistant bacteria are becoming increasingly responsible for neonatal deaths. As a result, researchers say improving antibiotic treatment is now one of the most urgent priorities in newborn care.
According to GARDP, NeoSep1 aims not only to improve survival but also to reduce unnecessary use of broad-spectrum antibiotics by identifying the most effective treatment combinations.
Alongside the clinical trial, researchers are strengthening laboratory surveillance, monitoring antimicrobial resistance trends and building research capacity across participating hospitals. This could improve neonatal care long after the study is completed. medfaq References:
* Landmark clinical trial to transform treatment options for newborns with sepsis expands to Asia - (https://gardp.org/landmark-clinical-trial-to-transform-treatment-options-for-newborns-with-sepsis-expands-to-asia/)
* Neonatal sepsis in India: Microbial profiles, antimicrobial-resistance patterns and diagnostic (and) management gaps - (https://ijmronline.org/archive/volume/13/issue/1/article/26394/pdf)
* NeoSep1 trial widens to find better sepsis treatment for newborns - (https://www.nature.com/articles/d44148-026-00074-3)
* The Impact of Neonatal Sepsis on Long-Term Neurodevelopment: A Systematic Review of Cognitive and Sensory Outcomes - (https://pmc.ncbi.nlm.nih.gov/articles/PMC12435795/)
Source-Medindia